View Single Post
  #3  
Old 08-22-2016, 02:45 PM
nasakido's Avatar
nasakido nasakido is offline
Senior Member
 
Join Date: Jun 2016
Posts: 127
Default Documentation sent by Aesculap on 08-22-2016

Main Website: Aesculap Activ-L

Patient Website for Activ-L: So Active, So Fast


Attached are brochures and information regarding the Aesculap Activ-L (pictures without any information were deleted within some of the .pdf attachments to shrink the overall size, ONLY if they were not necessary for product marketing):
  • Attachment #1: Lumbar Total Disc Replacement Reimbursement Resources
  • Attachment #2: Lumbar Total Disc Replacement A Patient’s Guide
  • Attachment #3: Lumbar Total Disc Replacement A Patient’s Tool "Motion Loss Index"
  • Attachment #4: Patient Information For the activL Artificial Disc Spike Endplate

Material Breakdown:

ActivL Superior and inferior end-plates
  • Chromium: 26-30%
  • Molybdenum: 5-7%
  • Iron: 0.75%
  • Manganese: 1% max
  • Silicon: 1% max
  • Carbon: 0.14% max or 0.15-0.35%
  • Nickel: 1% max
  • Nitrogen: 0.25% max
  • Cobalt: Percentage left
Coating over superior and inferior end-platesCore Insert
  • Polyethylene. "Polyethylene is a light, versatile synthetic resin made from the polymerization of ethylene," and "is of low strength, hardness and rigidity, but has a high ductility and impact strength as well as low friction. It shows strong creep under persistent force."

Additional Information:

Bioactive porous coating

Plasmapore® coated orthopaedic implants have been used successfully in joint replacement arthroplasty since 1986. The cementless implants are coated with a layer of fine titanium powder applied in a plasmaspray process under vacuum. The Plasmapore® pore sizes range from 50 to 200 μm with a microporosity of 35 % and a thickness of 0.35 mm.

These characteristics are optimal for bone ingrowth. Plasmapore® is a very rough surface and supports primary stability better than alternative coatings.

Highly crystallized calcium phosphate (CaP) is used as the bioactive material for Plasmapore® μ-CaP. The Plasmapore® surface is combined with a very thin CaP layer of 20 μm, which is applied electrochemically. This Plasmapore® μ-CaP surface accelerates direct bone-implant contact and resorbs without giant cell reactions within 8-12 weeks.


Plasmapore® with Dicalcium Phosphate

The well-known characteristics of calcium phosphates such as HAC (hydroxylapatite) and TCP (tricalcium phosphate), and various HAC/TCP combinations led to Aesculap’s selection of dicalcium phosphate dehydrate (CaHPO4 x 2H2O) for use with Plasmapore®.

Dicalcium phosphate dehydrate (DCPD) is very soluble in vivo, and dissolves into calcium and phosphate ions. During the acellular dissolving process, calcium and phosphate ions are continuously released in a ratio of 1:1, which are then available for bone modeling.

In contrast, the poorly soluble hydroxyapatite (HAC) releases only calcium ions from non-HAC calcium compounds (CaO) resulting from the manufacturing process, but almost no phosphate ions.

The resorbable tricalcium phosphate (TCP) stimulates giant cell reactions, and is therefore not optimal for use with orthopaedic implants. In orthopaedic implants the transition between primary and secondary implant stability is a continuous process of bone remodeling, characterized by apposition and resorption at the implant surface. The DCPD layer supports the continuous release of calcium and phosphate ions and encourages the formation of new bone structures at the bone-implant interface. Due to the continuous dissolving process of the calcium phosphate, the pores of the Plasmapore® coating remain open for bony ingrowth.


Improved bone contact

The features of thin calcium phosphate surfaces are important in the short postoperative term. The dicalcium phosphate μ-CaP layer is resorbed within 8-12 weeks in vivo. The dissolving process takes place without any giant cell activity. Simulation tests of the solution behavior of HAC and μ-CaP show a different ion release of μ-CaP in comparison to hydroxylapatite ceramic surfaces. HAC surfaces do not release phosphate ions but in the initial solution phase, calcium ions are released from non-HAP calcium compounds (CaO) resulting from certain manufacturing processes. In contrast, μ-CaP dicalcium phosphate releases phosphate and calcium ions during the entire resorption period with a ratio of 1:1. These ions are available for bone synthesis. Due to the osteoconductive characteristics of calcium phosphate, the bone is brought into direct contact with the implant surface.
__________________
Injury 31-7-14
MRI w/o con. 30-8-14
RT L5-S1 Discectomy w/ RT S1 Foraminotomy 21-11-14
PT (50) 20-8-14 to 04-24-15
MRI w/ con 13-4-15
XR Pelvis 08-6-15
COR INJ 02-7-15
MRI 14-11-15
Discography w/ CT-Scan 19-1-16
QME 16-2-16
XR LL 29-4-16
Bone Density (DEXA) Scan 01-8-16
XR LL 01-8-16
Metal-LTT 12-8-16
MRI 17-8-16
EKG 21-10-16
2-LVL L4-S1 ADR LP-ESP 08-11-16
XR LL 24-11-16
A-THX (24) 12-12-16 to 24-02-17
XR LL 31-01-17
XR LL 08-5-17
CT-Scan 07-6-17

Last edited by nasakido; 08-23-2016 at 10:05 PM. Reason: Adding brochure for Plasmapore coatings
Reply With Quote